Agree: Excellagen alone is worth 2.00 a share. But here we are. While we cannot know with certainty because there are no corporate communications, my personal observation is that they are forced to sell GNBT shares at .22 to raise money to get the vaccine IND prepared and approved, to stand up their patient support platform, to build out Excellagen manufacturing and marketing capacity and whatever else is going on. Even the cost of a press release can be measured in further sale of GNBT shares at .22, and for their trouble cost them another penny on the share price. It’s a rough situation all around. Game changers? Notification that the IND application has been submitted and/or approved; the Excellagen funding; even a whiff of revenue from a Florida and Arizona...so we wait. And try not to listen to the voices of those who would redefine this period of uncertainty and ambiguity as ‘bad news!’ when in fact it’s only uncertainty and ambiguity. If bad news is to come it will be ‘later’. If good news is to come it will be ‘later.’ In the interim, embrace uncertainty, embrace ambiguity as unavoidable parts of life and surprise! even investing.

If you need certainty there are always EE savings bonds.